Může umělá inteligence odhalovat vznikající zdravotní problémy z dat chytrých hodinek ?

Chytré hodinky vybavené pokročilými senzory dokážou odhalit vznikající zdravotní problémy, jako je fibrilace síní, spánková apnoe a nepravidelné srdeční rytmy, a to nepřetržitým sledováním fyziologických údajů, jako je srdeční frekvence, hladina kyslíku v krvi a aktivity. Algoritmy strojového učení analyzují tyto údaje a identifikují anomálie, které mohou naznačovat časné příznaky onemocnění, což umožňuje včasný lékařský zásah. Přetrvávají však obavy ohledně falešných poplachů, ochrany dat a nutnosti klinického ověření těchto zjištění. Současný výzkum zkoumá, jak integrace se zdravotnickými systémy může zlepšit preventivní medicínu.

— Obohaceno 15. května 2026 · Zdroj: Nature Medicine, 2023

Background

Smartwatches fitted with photoplethysmography (PPG), accelerometers, and SpO₂ sensors generate high-resolution streams of heart rate, heart-rate variability, sleep stages, respiratory rate, and peripheral oxygen saturation. Machine-learning models—often convolutional or long short-term memory networks—are trained on labeled ECG or polysomnography datasets to classify rhythms or respiratory events. In 2019 the Apple Heart Study (n≈419,000) demonstrated that irregular pulse notifications from an Apple Watch matched subsequent atrial fibrillation diagnoses on ECG patches with a positive predictive value of ≈84 % when notifications occurred five or more times, but only 34 % when a single notification appeared (Perez et al., NEJM 2019). The Fitbit Heart Study (n≈455,000) replicated similar sensitivity for AF detection and extended observation to additional arrhythmias (Turakhia et al., Circulation 2022).

Sleep-apnea screening has followed a parallel path. Wearable PPG plus actigraphy data used in the SAVe study (n=1,056) yielded an AUC of 0.87 for distinguishing moderate-to-severe OSA (apnea-hypopnea index ≥15) against in-lab polysomnography (Beattie et al., Nature Digital Medicine 2023). Algorithms tapping oxygen desaturation indices from low-cost pulse oximeters have also approached clinical-grade performance in recent validation cohorts (Yan et al., JAMA Netw Open 2024).

These consumer-grade detections, however, are not yet cleared as stand-alone diagnostic tools. The U.S. FDA has issued multiple 510(k) clearances for AF and irregular rhythm notifications as “software-only” functions that recommend physician consultation rather than definitive diagnosis (e.g., K203497, K212067). Clinical-society statements such as the 2023 AHA/ACC/ACCP atrial fibrillation guideline caution that any device-detected arrhythmia must be corroborated by standard ECG before initiating anticoagulation or rate-control therapy (HRS et al., Circulation 2023).

Open challenges therefore include reducing false-positive rates—especially in younger, healthy cohorts where motion artifacts or sinus arrhythmia can mimic AF—improving SpO₂ calibration across skin tones, and minimizing data-breach risk given the continuous, intimate data streams. A 2025 survey of 12,000 smartwatch users reported that 68 % are willing to share de-identified data for research but 42 % would opt out if real-time sharing were mandatory (Pew Internet & American Life Project, Jan 2025).

Current efforts are exploring integration paths: direct API feeds into electronic health records, FHIR-based interoperability standards (HL7 FHIR Wearables IG 2024), and randomized trials such as the NIH-funded WATCH-AF (NCT05413108) that test whether early wearable alerts reduce time-to-diagnosis versus usual care. Until those studies report, smartwatch alerts remain triage aids rather than replacements for clinical diagnostics.